1、因廠家會在沒有任何提前通知的情況下更改產(chǎn)品價格、包裝、產(chǎn)地或者一些附件,若出現(xiàn)價格異常請以廠家官網(wǎng)價格為準(zhǔn),本司不能確??蛻羰盏降呢浳锱c商城圖片、產(chǎn)地、附件說明完全一致,只能確保為原廠正貨!并且保證與當(dāng)時市場上同樣主流新品一致。若本商城沒有及時更新,請大家諒解!
2、商品信息標(biāo)注“一般危化品”“?;钡纳唐?,如需購買需提供一般危化品購買資質(zhì)。
3、僅可用于工業(yè)或者科研等非醫(yī)療目的。買賣雙方確認(rèn):依照中國法律法規(guī)之規(guī)定,本網(wǎng)站銷售的所有產(chǎn)品僅用于工業(yè)應(yīng)用或者科學(xué)研究等非醫(yī)療目的,不可用于人類或動物的臨床診斷或治療,非藥用,非食用。我們特此明示提醒:您應(yīng)嚴(yán)格恪守上述規(guī)定,不得超越正常的科研或教學(xué)目的而違規(guī)使用產(chǎn)品,否則由此造成的一切后果均應(yīng)由您承擔(dān);若我們因此遭受任何損失的,您也應(yīng)負(fù)責(zé)對我們做出賠償。
CAS:936890-98-1
中文名:OSI-027
英文名:OSI-027
中文別名:
英文別名:
性質(zhì):
OSI-027 的生物活性
OSI027 is a potent mammalian target of rapamycin (mTOR) kinase inhibitor. OSI027 has potential antineoplastic activity. MTOR kinase inhibitor OSI-027 binds to and inhibits both the raptor-mTOR (TOR complex 1 or TORC1) and the rictor-mTOR (TOR complex 2 or TORC2) complexes of mTOR, which may result in tumor cell apoptosis and a decrease in tumor cell proliferation. MTOR is a serine/threonine kinase that is upregulated in some tumors and plays an important role downstream in the PI3K/Akt/mTOR signaling pathway.
OSI027 acts as a potent suppressor of primitive leukemic precursors. OSI027 much more effective than rapamycin in eliciting antileukemic effects in vitro. OSI027 induces apoptosis of different types of cells transformed by the T315I-BCR-ABL mutation, which confers resistance to imatinib mesylate, nilotinib, and dasatinib. [1][2][3]
OSI-027 參考文獻(xiàn)
[] Clin Cancer Res 2011;17:4378-4388
[] PNAS July 13, 2010;107:12469–12474
[] Autophagy October 1, 2010;6:7, 966-967
儲存:
安全術(shù)語:
風(fēng)險術(shù)語:
危險品標(biāo)志:
危險品運輸編號: